CALYPTE BIOMED - 500 Beiträge pro Seite

[ultimo]

hi

ist calypte tot oder geht irgendwann noch was?

fällt heute auf 0,016€

wars das

eure meinungen würden mich freuen.

mfg

[ohshit]

Es gibt schon wahrlich genug Threads zu dieser Bude....

[Marco111]

Diese Frage ist schnell beantwortet:

- Umsätze der Firma sinken
- Verlust zum Vorjahr hat sich verdoppelt
- Banken geben kein Geld mehr
- Anleihen von 800 Mio. treiben die Aktienmenge in Höhen
die den Kurs völlig verwässern.
- KGV wird es nie geben
- Betrügerladen schon seit 4 Jahren
- Schon vor 3 jahren wollte man in china super Gewinne
machen.
- Nun in china dank SARS keine Umsätze mehr.
und und und....

[ultimo]

hi

Calypte Biomedical Corporation Holds Annual Meeting of Shareholders
Wednesday May 21, 9:03 am ET
Obtains Shareholder Approval for All Agenda Items


ALAMEDA, Calif.--(BUSINESS WIRE)--May 21, 2003--Calypte Biomedical Corporation (OTCBB:CALY - News), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western blot supplemental test, announces that it received shareholder approval for proposals submitted to shareholders at its Annual Meeting of Shareholders held May 20, 2003.
Specifically, shareholders approved an amendment to the Company`s Amended and Restated Certificate of Incorporation to implement a reverse stock split of the outstanding shares of the company`s common stock at a ratio of 1:30. The company`s authorized shares of common and preferred stock will not be affected by the reverse split which is expected to be effective May 27, 2003.

In addition to approval of the reverse split of outstanding shares of common stock, shareholders also approved proposals to increase the number of common shares reserved for issuance under the company`s 2000 Equity Incentive, 1995 Director Option, and 1995 Employee Stock Purchase Plans.

"We are very pleased that all agenda items presented obtained shareholder approval at our Annual Meeting," stated Anthony Cataldo, Calypte`s chairman. "We look forward to the continued support of our shareholders."

[ultimo]

hi

calypte macht reverse split

1:30

obs was bringt?

Calypte Implements Reverse Stock Split
Wednesday May 28, 9:07 am ET
$15 Billion Emergency Plan for AIDS Relief Signed by President Bush


ALAMEDA, Calif.--(BUSINESS WIRE)--May 28, 2003--Calypte Biomedical Corporation (OTCBB:CALY - News), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced that it has been informed by the Over the Counter Bulletin Board (OTCBB) that its common stock, following the 1:30 reverse stock split approved by its stockholders on May 20, 2003, will trade temporarily under the symbol CYPTV beginning today. Calypte expects that its common stock will ultimately trade on the OTCBB under the symbol CYPT. The new stock symbol and post-split trading will be effective at the opening of the OTCBB on Wednesday, May 28, 2003.
"This restructuring is the cornerstone of our ongoing plans to add value and growth, that along with our government initiatives, we believe will allow us to utilize such opportunities as the Emergency Plan for AIDS Relief signed yesterday, which provides for significant prevention efforts, including voluntary testing and counseling," said Anthony Cataldo, Executive Chairman of Calypte Biomedical.

"Calypte, along with many other companies and organizations in the U.S. and abroad, are committed to helping the most HIV/AIDS afflicted countries around the globe."

About Calypte Biomedical:

Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte`s tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found at www.calypte.com.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management`s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company`s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company`s success are more fully disclosed in the Company`s most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC

[ultimo]

hi

reverse split geglückt

aktuell bei 0,37 $


mfg

[mavridis]

Sag mal die neuen Aktien in Frankfurt haben eine andere WKN was passiert mit den alten die stehen bei mir immer noch so wie sie waren !?

[gino]

Die "neuen" Aktien sind noch nicht ins Depot umgebucht worden. Die alte WKN existiert dann nicht mehr. Ich denke morgen oder am Montag hast Du 30:1 weniger Aktien und eine neue WKN (765254). Naja, dafür ist der Kurs auch etwas höher!!

Gruß
gino

[ultimo]

hi

caly wird noch ein großer gewinner werden


zeit muß man haben

kurs wird ende des jahres bei 2,50€ sein

mfg

[okujawa]

Aus welchem Kaffeegrund hast du diese Voraussage gedeutet ?
Gruß
OK

[ultimo]

ok

kein kaffeesatz

sondern logische überlegung

alle bios habens schwer gehabt

ein kleiner erfolg oder übernahme und es geht ab.

abwarten und tee trinken

hat sich bei mir immer noch bestätigt.

mfg

[mavridis]

Meinst du wirklich wenn Caly übernommen wird, das der Kurs auf 2,5 (ehemals 0,08) Euro stehen wird ?

Ich tippe mal zwischen 100 und 250 ( ehemals 3,33 und 8,33 ) Euro.......

Caly hat nur ein grosses Proplem und das heisst:

Umsatz und Liquität........ändert sich da was !

Sind wir MILLIONÄRE !!!!!!!!!!!

So und jetzt träumen wir mal weiter.......

[Aeppler]

Hat schon jmd den Umtausch seiner neuen Stücke unter der ISIN NEU US1317226058 im Depot?

*ReSplit 28.05. 30:1
*Resplit 29.05. 30:1 (oder vertippt evtl. 1:30?)



* Comdirect

Wieso 2 ReSplits?



@eppler

[ultimo]

hi

bei mir auch noch nicht gebucht

das is im moment die hemmung sonst würde mehr abgehen

ich glaube am 15.06. wird eingebucht

mfg

[ultimo]

.............oder meint ihr im ernst die würde keiner

mehr handeln

warts ab

[ultimo]

jetzt sind se eingebucht

aktuell in usa + 13,64 %

schaun mer mal